Amid GlaxoSmithKline's ($GSK) major push to expand in China, the London-based drugmaker has located a new R&D unit in that country that will investigate traditional Chinese medicines. The move is part of an effort to discover new chemical entities for treating diseases, British newspaper The Telegraph reported Sunday. Last week GSK R&D honcho Moncef Slaoui shared the plans with FierceBiotech in an interview about the drugmaker's strategy for discovering and developing new products. FierceBiotech's Slaoui interview | The Telegraph report